Here it is In addition to reviewing highlights from last year, both Ms. Svoronos and Mr. Luc Tanguay, respectively Chair of the Board and President and CEO of Theratechnologies, addressed people present at the meeting.
“At the same time last year, I said that Theratechnologies was entering a new era. A year later, the numbers speak for themselves. In fact, this is only the beginning and the Board is completely supportive of the plan being methodically implemented by Management. Theratechnologies has been on the path of success and growth for several years now and the future looks even brighter,” said Dawn Svoronos, Chair of the Board, Theratechnologies Inc.
“Given how the Company is evolving, we are now actively assessing a listing on NASDAQ. Furthermore, in a few weeks from now, we should be in a position to share our strategic plan for NAFLD/NASH,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
“A year into the launch of Trogarzo® in the United States, we strongly believe that we are on track to generate sales of at least five times those of EGRIFTA® in the coming years. This is not even taking into account the potential contribution of Europe where we are awaiting the recommendation from the CHMP,” added Luc Tanguay.
“While revenues keep growing strongly, our goal is also to give the Company a longer term horizon. This is one of the arguments behind the acquisition of a unique platform in oncology which has already shown promising results in pre-clinical trials,” concluded Mr. Tanguay.
FTV.